Pershing Edward
SEC insider (Form 3/4/5 filer). CIK 0001689739. CEO at PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT). 113 reported Form 4/5 transactions since Sep 2024; latest on Oct 23, 2026. Located in KNOXVILLE, TN.
Companies Pershing Edward has filed insider reports for
- PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT): Director, Officer, 10% Owner, CEO
Pershing Edward
CIK: 0001689739
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
PROVECTUS BIOPHARMACEUTICALS, INC.
Discretionary Trading P&L
Holdings
Transaction History (113 total)
- Oct 23, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirectSeries D-1 Convertible Preferred Stock
7.6K shares- - Oct 23, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirect8% Unsecured Convertible Promissory Note
0 shares- - Oct 10, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirectSeries D-1 Convertible Preferred Stock
22.6K shares- - Oct 10, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirect8% Unsecured Convertible Promissory Note
0 shares- - Oct 3, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirectSeries D-1 Convertible Preferred Stock
13.2K shares- - Oct 3, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirect8% Unsecured Convertible Promissory Note
0 shares- - Sep 18, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirect8% Unsecured Convertible Promissory Note
0 shares- - Sep 18, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirectSeries D-1 Convertible Preferred Stock
13.2K shares- - Sep 11, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirectSeries D-1 Convertible Preferred Stock
13.2K shares- - Sep 11, 2026PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
ExerciseDirect8% Unsecured Convertible Promissory Note
0 shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 23, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise Series D-1 Convertible Preferred Stock | 7,599 | - | - | Direct |
| Oct 23, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise 8% Unsecured Convertible Promissory Note | 0 | - | - | Direct |
| Oct 10, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise Series D-1 Convertible Preferred Stock | 22,609 | - | - | Direct |
| Oct 10, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise 8% Unsecured Convertible Promissory Note | 0 | - | - | Direct |
| Oct 3, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise Series D-1 Convertible Preferred Stock | 13,216 | - | - | Direct |
| Oct 3, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise 8% Unsecured Convertible Promissory Note | 0 | - | - | Direct |
| Sep 18, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise 8% Unsecured Convertible Promissory Note | 0 | - | - | Direct |
| Sep 18, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise Series D-1 Convertible Preferred Stock | 13,216 | - | - | Direct |
| Sep 11, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise Series D-1 Convertible Preferred Stock | 13,216 | - | - | Direct |
| Sep 11, 2026 | PVCT PROVECTUS BIOPHARMACEUTICALS, INC. | Exercise 8% Unsecured Convertible Promissory Note | 0 | - | - | Direct |
1-10 of 113 transactions